Tag: JNIS

SWIFT-DIRECT sub-analysis finds effect of bridging thrombolysis is preserved over time

A recent sub-analysis of the SWIFT-DIRECT trial, which is published in the Journal of NeuroInterventional Surgery (JNIS), has found “no evidence” that the effect...

Abnormal DW-MRI foci “significantly more frequent” with radial versus femoral access

A prospective analysis of 200 consecutive diagnostic cerebral angiograms has indicated that the number of diffusion-weighted magnetic resonance imaging (DW-MRI) restriction foci was “significantly...

J Mocco becomes 27th Society of NeuroInterventional Surgery president

J Mocco, an endovascular neurosurgeon at Mount Sinai in New York City, USA has been named the 2022 president of the Society of NeuroInterventional...

SNIS 2022: Direct triage to Level 1 stroke centres reduces time...

Implementing severity-based field triage leads to faster treatment and less disability for stroke patients, according to late-breaking research presented recently at the Society of...

Route 92’s Monopoint operating platform shows 82% first-pass effect in independent...

Route 92 Medical recently announced the publication of an investigator-initiated, multicentre SLIC (Super large-bore ingestion of clot) study of its proprietary Monopoint operating platform,...

Route 92 publishes data demonstrating 80% first-pass effect with novel thrombectomy...

Route 92 Medical has announced the publication of initial results from the SUMMIT NZ clinical trial—a single-arm, multicentre, prospective trial evaluating its proprietary Monopoint...
michael chen

Michael Chen

Michael Chen—a neurointerventionist and professor of Neurology, Neurosurgery and Radiology at Rush University Medical Center in Chicago, USA—speaks to NeuroNews to provide insight on...

Guidewire-less neurovascular navigation system shows promise in rabbit aneurysm model

A new concept for navigating the neurovasculature, performed without the aid of a guidewire, has demonstrated its ability to be manoeuvred through tortuous vessels,...

Lack of evidence among challenges that must be overcome to realise...

In spite of the clinical successes observed to date, a lack of high-level safety and efficacy evidence, among other current challenges and limitations, must...

CereVasc announces publication of first-in-human case report with eShunt system

CereVasc has announced the publication of a case report detailing the first treatment in a study of its eShunt system—an investigational device intended to...
Diversion-p64 study

Large prospective study demonstrates high efficacy and low mortality rates with...

The Diversion-p64 study—the largest prospective study using the p64 flow modulation device (phenox) to date—has demonstrated that the device has a high level of...